Model development
CPH
Separate CPH models were developed for each of the clinical endpoints using data from the CheckMate 9ER trial. The impact of cabozantinib exposure on relative hazard was evaluated during base model development. A drop in − 2 log likelihood (− 2LL) when including cabozantinib exposure in the CPH model was considered significant. Both linear (Eq. 